Myeloperoxidase (MPO) is an enzymatic mediator of several inflammatory cascades and higher serum levels have been associated with increased risk of adverse cardiovascular events. We investigated the association of serum MPO with the ankle–brachial index (ABI) and peripheral arterial disease (PAD) in a bi-ethnic cohort of African-Americans and non-Hispanic white individuals. Participants included 1324 African-Americans (mean age 64 years, 71% women) and 1237 non-Hispanic white individuals (mean age 59 years, 57% women) belonging to hypertensive sibships. Serum levels of MPO were measured by solid phase sandwich immunoassay. ABI was measured using a standard protocol and PAD was defined as an ABI < 0.90. Multivariable regression analysis using generalized estimating equations were performed to assess whether serum MPO levels were associated with ABI and the presence of PAD. After adjustment for age and sex, higher MPO levels were significantly associated with lower ABI and the presence of PAD in African-Americans (p = 0.004 and p = 0.005, respectively) and in non-Hispanic white individuals (p = 0.001 and p = 0.016, respectively). After additional adjustment for conventional risk factors (diabetes, smoking status, total and high-density lipoprotein cholesterol, waist circumference, hypertension), prior history of myocardial infarction or stroke, and medication use (statins, aspirin, estrogen), higher MPO levels remained significantly associated with lower ABI and the presence of PAD in both African-Americans (p = 0.008 and p = 0.010, respectively) and non-Hispanic white individuals (p = 0.001 and p = 0.018, respectively). We conclude that higher MPO levels are associated with lower ABI and the presence of PAD in African-Americans and non-Hispanic white individuals.
1 Ross R . Atherosclerosis – an inflammatory disease. N Engl J Med1999; 340: 115–126.
2.
2 Podrez EA Schmitt D Hoff HF Hazen SL . Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest1999; 103: 1547–1560.
3.
3 Sugiyama S Okada Y Sukhova GK Virmani R Heinecke JW Libby P . Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol2001; 158: 879–891.
4.
4 Eiserich JP Baldus S Brennan ML . Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science2002; 296: 2391–2394.
5.
5 Vita JA Brennan ML Gokce N . Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation2004; 110: 1134–1139.
6.
6 Klebanoff SJ . Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med1980; 93: 480–489.
7.
7 Heinecke JW . Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. Faseb J1999; 13: 1113–1120.
8.
8 Podrez EA Abu-Soud HM Hazen SL . Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med2000; 28: 1717–1725.
9.
9 Daugherty A Dunn JL Rateri DL Heinecke JW . Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest1994; 94: 437–444.
10.
10 Meuwese MC Stroes ES Hazen SL . Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol2007; 50: 159–165.
11.
11 Zhang R Brennan ML Fu X . Association between myeloperoxidase levels and risk of coronary artery disease. JAMA2001; 286: 2136–2142.
12.
12 Buffon A Biasucci LM Liuzzo G D’Onofrio G Crea F Maseri A . Widespread coronary inflammation in unstable angina. N Engl J Med2002; 347: 5–12.
13.
13 Brennan M-L Penn MS Van Lente F . Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med2003; 349: 1595–1604.
14.
14 Baldus S Heeschen C Meinertz T . Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation2003; 108: 1440–1445.
15.
15 Regensteiner JG Hiatt WR . Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med2002; 112: 49–57.
16.
16 Hirsch AT Haskal ZJ Hertzer NR . ACC/AHA Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation2006; 113: e463–e654.
17.
17 Wildman RP Muntner P Chen J Sutton-Tyrrell K He J . Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999–2002. Am J Cardiol2005; 96: 1579–1583.
18.
18 Tzoulaki I Murray GD Lee AJ Rumley A Lowe GD Fowkes FG . C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation2005; 112: 976–983.
19.
19 Silvestro A Scopacasa F Ruocco A . Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med2003; 8: 225–232.
20.
20 Gerszten RE Accurso FJ Bernard GR . Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol2008; 295: L16–L22.
21.
21 Boerwinkle E . Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP). Hypertension2002; 39: 3–9.
22.
22 Hiatt WR . Medical treatment of peripheral arterial disease and claudication. N Engl J Med2001; 344: 1608–1621.
23.
23 Zeger SL Liang KY . Longitudinal data analysis for discrete and continuous outcomes. Biometrics1986; 42: 121–130.
24.
24 Leeuwenburgh C Rasmussen JE Hsu FF Mueller DM Pennathur S Heinecke JW . Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem1997; 272: 3520–3526.
25.
25 Leeuwenburgh C Hardy MM Hazen SL . Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem1997; 272: 1433–1436.
26.
26 Hazen SL Zhang R Shen Z . Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res1999; 85: 950–958.
27.
27 Heinecke JW Li W Francis GA Goldstein JA . Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest1993; 91: 2866–2872.
28.
28 Hazell LJ Stocker R . Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J1993; 290: 165–172.
29.
29 Zheng L Nukuna B Brennan ML . Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest2004; 114: 529–541.
30.
30 Zheng L Settle M Brubaker G . Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem2005; 280: 38–47.
31.
31 Bergt C Pennathur S Fu X . The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A2004; 101: 13,032–13,037.
32.
32 Marsche G Hammer A Oskolkova O Kozarsky KF Sattler W Malle E . Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem2002; 277: 32,172–32,179.
33.
33 Harrison DG . Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest1997; 100: 2153–2157.
34.
34 Forgione MA Leopold JA Loscalzo J . Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol2000; 15: 409–415.
35.
35 Abu-Soud HM Hazen SL . Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem2000; 275: 37,524–37,532.
36.
36 Peppin GJ Weiss SJ . Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc Natl Acad Sci U S A1986; 83: 4322–4326.
37.
37 Shabani F McNeil J Tippett L . The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. Free Radic Res1998; 28: 115–123.
38.
38 Fu X Kassim SY Parks WC Heinecke JW . Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem2001; 276: 41,279–41,287.
39.
39 Brevetti G Schiano V Laurenzano E . Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J2008; 29: 224–230.
40.
40 Wang TJ Gona P Larson MG . Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med2006; 355: 2631–2639.
41.
41 Zethelius B Berglund L Sundstrom J . Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med2008; 358: 2107–2116.
42.
42 Fung ET Wilson AM Zhang F . A biomarker panel for peripheral arterial disease. Vasc Med2008; 13: 217–224.
